IRCT20120624010104N7 IRCT 2021-01-24 Ahran Tejarat Pharmaceutical Company Ursodeoxycholic acid in cholelithiasis Evaluation of bioequivalency of Ursodeoxycholic acid capsule of Ahran Tejarat Company compared to Ursoflor® on 24 volunteers. 2021-06-22 anticipated 24 Complete https://irct.ir/trial/53692 interventional Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Crossover, Purpose: Health service research. Bioequivalence . Intervention 1: Each volunteer take 2 times the medication at least a week apart. Intervention group: 1 -24 volunteers after their health is confirmed by the project doctor and signed the consent form is submitted to the project. 2 - In the fasting position 2 Ursodiol capsule 300 mg of Ahran Tejarat Company as a test product is prescribed with a glass of water (single Dose) 3 - At intervals of 0) before the administration of the drug), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 24, 48, 72 hours after the administration of the drug, blood is taken from the volunteers. 4 -Isolated plasma transfer to the analysis laboratory to determine the amount of drug by HPLC method. Intervention 2: After at least a week apart: Intervention group: 1 -24 volunteers after their health is confirmed by the project doctor and signed the consent form is submitted to the project. 2 - In the fasting position 2 Ursoflor® capsule 300 mg of company So.Se.PHARM as reference is prescribed with a glass of water (single Dose) 3 - At intervals of 0) before the administration of the drug), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 10, 24, 48, 72 hours after the administration of the drug, blood is taken from the volunteers. 4 -Isolated plasma transfer to the analysis laboratory to determine the amount of drug by HPLC method. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is Confidential